Structure Therapeutics, Inc. Sponsored ADR (GPCR) AI Stock Analysis

• Market Cap: $5.45B
• Dividend Yield: N/A
• Average Volume (3M): 1.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: -64.91%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 70,639,190
• 10 Day Avg. Volume: 914,585
• 30 Day Avg. Volume: 1,020,480
• PEG Ratio: 3.15
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.11
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -6.88K
• Enterprise Value/Ebitda: -19.84
• 1Y Price Target: $106.50
• Price Target Upside: 27.12% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): -1.38
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: $99.00 ▲(18.17% Upside)

The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), partially offset by a strong balance sheet and meaningful positive corporate catalysts (clinical progress and a $100M non-dilutive licensing payment). Technicals are strong but look overbought, and valuation support is limited due to negative earnings and no dividend yield.

Positive Factors

Balance Sheet Strength

Low leverage and substantial assets provide a durable capital buffer to fund clinical R&D and absorb development volatility. A strong equity base improves strategic optionality for partnerships or asset sales, supporting multi-quarter operations without immediate insolvency risk.

Non-dilutive Licensing Deal

The $100M upfront from Genentech/Roche materially extends runway without issuing equity and validates Structure’s oral GLP-1 IP. Retaining control of its own programs preserves upside while providing durable non-dilutive capital to support Phase 3 planning and execution.

Clinical Progress on Aleniglipron

Robust Phase 2b and exploratory data de-risk the lead oral GLP‑1 asset and justify a planned Phase 3 start. Clinical validation enhances partnerability and the program’s long-term commercial potential, strengthening strategic positioning in the obesity therapeutics market.

Negative Factors

No Product Revenue

Absence of product revenue means the company depends entirely on financing and partnerships to fund operations. Continued negative EBIT and widening net losses imply ongoing cash depletion until commercialization, increasing execution and funding risk over the medium term.

High Cash Burn

Sustained, large negative operating and free cash flows—worse than prior years—create runway pressure. Persistent cash burn forces recurring financings or milestone-dependent deals, constraining strategic flexibility and elevating the importance of near-term clinical success.

Reliance on Capital Markets

A sizable $650M offering underscores dependence on external funding to advance programs. While proceeds relieve short-term liquidity needs, frequent reliance on capital markets increases dilution risk and ties program continuity to successful clinical readouts or partnership milestones.

Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model

Company Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

How the Company Makes Money

Structure Therapeutics, Inc. generates revenue through the development and commercialization of its drug candidates. The company makes money by advancing its compounds through clinical trials and seeking regulatory approval for market entry. Once approved, these drugs can be licensed or sold to pharmaceutical companies or healthcare providers, generating income through sales, royalties, or milestone payments. Additionally, the company may engage in strategic partnerships or collaborations with other biopharmaceutical firms, which can provide funding, shared resources, and expertise in exchange for a share in the profits or rights to market the developed therapies. These partnerships and collaborations often play a significant role in the company's revenue model, offering both financial support and expanded market reach.

Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview

Summary

Financial profile is mixed: the balance sheet is strong with minimal debt (~$7.1M) versus equity (~$770.0M), but the company has no revenue and widening losses (TTM EBIT about -$248M; net loss about -$211M) alongside heavy cash burn (TTM FCF about -$196M), which raises sustainability risk without a clear path to profitability.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and very large operating losses (EBIT of about -$248M; net loss of about -$211M), indicating the business is still in heavy investment mode. Losses have widened meaningfully versus 2024 (net loss about -$123M) and 2023 (about -$90M), highlighting increasing expense intensity and weak earnings trajectory. The main positive is that the balance sheet (not the P&L) appears to be funding these losses without meaningful leverage, but near-term profitability is not in sight based on the data provided.

Balance Sheet

The balance sheet is a relative strength: TTM (Trailing-Twelve-Months) debt is low (~$7.1M) versus equity (~$770.0M), reflecting minimal leverage and strong capitalization. Assets remain substantial (~$832.2M). A key weakness is shareholder returns: return on equity is negative in the most recent periods (TTM around -21%), consistent with ongoing losses. Equity also improved materially versus earlier years (negative equity in 2020–2022 to positive in 2023–TTM), but profitability must improve to sustain long-term balance sheet strength.

Cash Flow

Cash burn remains heavy: TTM (Trailing-Twelve-Months) operating cash flow is about -$194M and free cash flow about -$196M, worse than 2024 (roughly -$117M free cash flow) and 2023 (roughly -$82M). While free cash flow is closely aligned with net loss (free cash flow to net income near 1x), that mainly indicates losses are translating into real cash outflows rather than being cushioned by non-cash items. The one offset is that free cash flow showed a positive growth rate in the TTM data versus the prior period, but absolute cash consumption is still very high.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-686.98K	0.00	0.00	0.00	0.00	-20.03K
EBITDA	-238.30M	-157.24M	-102.48M	-52.28M	-37.62M	-15.75M
Net Income	-210.69M	-122.53M	-89.62M	-51.32M	-40.01M	-15.90M
Balance Sheet
Total Assets	832.16M	903.33M	482.02M	97.84M	111.16M	38.70M
Cash, Cash Equivalents and Short-Term Investments	799.04M	883.52M	467.32M	90.84M	107.31M	37.45M
Total Debt	7.09M	3.86M	5.45M	260.00K	621.00K	280.00K
Total Liabilities	62.14M	38.49M	29.05M	212.99M	175.89M	61.17M
Stockholders Equity	770.02M	864.84M	452.97M	-115.14M	-64.73M	-22.47M
Cash Flow
Free Cash Flow	-196.38M	-117.93M	-81.66M	-46.27M	-33.37M	-14.30M
Operating Cash Flow	-194.25M	-116.64M	-79.49M	-46.12M	-32.16M	-14.28M
Investing Cash Flow	66.89M	-358.91M	-268.34M	-62.11M	17.86M	-21.15M
Financing Cash Flow	58.14M	515.26M	451.53M	29.01M	103.25M	25.84M

Structure Therapeutics, Inc. Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 83.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Positive. The current price of 83.78 is above the 20-day moving average (MA) of 82.74, above the 50-day MA of 65.82, and above the 200-day MA of 34.21, indicating a bullish trend. The MACD of 6.58 indicates Positive momentum. The RSI at 57.27 is Neutral, neither overbought nor oversold. The STOCH value of 28.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GPCR.

Structure Therapeutics, Inc. Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GPCR	62 Neutral	$5.45B	-22.94	-25.31%	―	―	-64.91%
STOK	61 Neutral	$1.76B	51.20	15.02%	―	1128.17%	―
SNDX	55 Neutral	$1.86B	-5.88	-129.32%	―	597.19%	0.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZYME	50 Neutral	$1.75B	-27.68	-18.46%	―	116.21%	43.93%

Structure Therapeutics, Inc. Sponsored ADR Corporate Events

Structure Therapeutics inks major GLP-1 licensing deal

On December 30, 2025, Gasherbrum Bio, a subsidiary of Structure Therapeutics, entered into a non-exclusive licensing agreement with Genentech and Roche, granting them rights under certain Gasherbrum patents covering a distinct class of oral GLP-1 receptor agonists to develop and commercialize products containing Genentech’s proprietary compound CT-996. In return, Gasherbrum will receive a one-time $100 million payment within 30 days of signing and low single-digit royalties on net sales of CT-996 products until the relevant patents expire or a specified earlier date, while retaining full control over its own metabolic pipeline, as the license expressly does not encumber Structure’s ongoing programs, including aleniglipron and other GLP-1, dual amylin/calcitonin, and GIPR/GCGR modulators, and preserves Gasherbrum’s ability to terminate the deal in the event of material breach or patent challenges, providing a significant non-dilutive capital infusion without ceding broader strategic or patent prosecution rights.

The most recent analyst rating on (GPCR) stock is a Hold with a $73.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.

Structure Therapeutics Announces $650 Million Public Offering

On December 9, 2025, Structure Therapeutics, Inc. entered into an underwriting agreement to issue and sell American Depositary Shares (ADSs) and pre-funded warrants in a public offering. The offering is expected to generate approximately $650 million in gross proceeds, with the closing anticipated on December 11, 2025, subject to customary conditions. This move is part of the company’s strategy to raise capital, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (GPCR) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.

Structure Therapeutics Announces Positive Clinical Trial Results

On December 8, 2025, Structure Therapeutics announced positive results from its ACCESS clinical program for aleniglipron, a once-daily oral GLP-1 receptor agonist for obesity treatment. The Phase 2b ACCESS study showed significant weight loss with a 120 mg dose, while the exploratory ACCESS II study demonstrated even greater weight loss with a 240 mg dose. The findings support advancing to Phase 3 trials in mid-2026, potentially offering a scalable and accessible treatment option for obesity.

The most recent analyst rating on (GPCR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.